1 / 38

Menopause and Aging

Menopause and Aging. Sylvia Ziegenbein, MD M3 Student Lecture 2007. Objectives. Define menopause Describe associated changes and symptoms Treatment options for bothersome symptoms Review physiologic changes of aging, specific age related problems and screening in elderly. Case #1.

mercia
Download Presentation

Menopause and Aging

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Menopause and Aging Sylvia Ziegenbein, MD M3 Student Lecture 2007

  2. Objectives • Define menopause • Describe associated changes and symptoms • Treatment options for bothersome symptoms • Review physiologic changes of aging, specific age related problems and screening in elderly

  3. Case #1 • 35 yo G1 P0101 female presents with c/o hot flashes and amenorrhea for 12 months. She doesn’t know why this is happening, her sxs are worsening. She wants your help. • DDx • Tests

  4. Case #2 • 45 yo G2 P2002 female presents with c/o hot flashes and irregular menses (q 3-5 mos) for the past 9 months. She doesn’t know why this is happening, she wants your help. By the way, she wants your help to stop smoking also. • DDx • Tests

  5. Case #3 • 65 yo WF presents to start HRT. She heard it would help protect her heart, make her feel younger and help her memory. She went through menopause 10 years ago and has not had any problems except an occasional hot flash. She is 5’4”, 108 lbs. By the way, she had a wrist fx 2 yrs ago takes her Viactiv faithfully.

  6. Case #4 • 49 yo WF presence b/c she can’t stand her hot flashes anymore. She can’t sleep very well b/c she wakes up 3 times a night drenched with sweat. She is an executive at First National Bank. She has a history of breast cancer 2 years ago. “Please Dr. Ziegenbein, I need some hormones or something.”

  7. Case #5 • 55 yo BF returns to discuss stopping her HRT. She has been taking it for 5 years now with good relief of her vasomotor sxs.

  8. Case #6 • 53 yo WF began continuous HRT 4 wks ago. She is now having some vaginal spotting after being amenorrheic for 14 months. She is concerned.

  9. Menopause • Definition • Average Age • Related Sxs

  10. Classification System • STRAW System • Help communication

  11. Menopause Terminology: STRAW* Staging System Final Menstrual Period 0 Stages: -2 -1 +1 +2 Terminology: Menopausal Transition Postmenopause Early Late† Early† Late Perimenopause Duration of Stage: Variable 4 yrs Untildemise a b 1 yr Menstrual Cycles: Variable cycle length (>7 daysdifferent from normal) 2 skippedcycles and aninterval of amenorrhea(60 days) None Amen. × 12 mos. *STRAW = Stages of Reproductive Aging Workshop. †Stages most likely to be characterized by vasomotor symptoms. Soules MR, et al. Menopause. 2001;8:402-7.

  12. Vasomotor symptoms:Why don’t we treat every women with hormones?

  13. WHI: HRT vs Placebo • Large prospective RCT, 2002, JAMA • 16,608 postmenopausal women (50-79 y.o.) • Ave age at enrollment = 63 yrs • Two arms: • Estrogen + Progestin (Prempro 0.625/2.5), n=8506 • Placebo, n=8102 • Outcomes measured: • Primary : Coronary heart disease (CHD) and invasive breast cancer • Secondary : stroke, pulmonary embolism, DVT, endometrial CA, colorectal CA, hip and vertebral fractures and death from other causes

  14. HRT Arm: Stopped Early @ 5.2 yrs • Invasive Breast Cancer = 38 vs 30/10,000 person yrs (HR 1.26) • CHD = 37 vs 30/10,000 (HR 1.29) • Stroke = 29 vs 21/10,000 (HR 1.41) • Venous Thromboembolic disease = 34 vs 16/10,000 (HR 2.11) • Colorectal cancer = 10 vs 16/10,000 (HR 0.63) • Hip fracture = 10 vs 15/10,000 (HR 0.66) • Vertebral fracture = 9 vs 15/10,000 (HR 0.66) • No change in endometrial and lung cancer

  15. WHI: Estrogen Only vs Placebo • WHI 2004: JAMA • 10,739 postmenopausal women • s/p hysterectomy (50-79 y.o.) • Ave. age @ enrollment = 63.6 y.o. • Two arms: • Estrogen (Premarin 0.625 mg), n=5310 • Placebo, n=5429 • Outcomes: • Primary: CHD and invasive breast cancer • Secondary: stroke, pulmonary embolism, DVT, colorectal cancer, hip/vertebral fractures and death from other causes

  16. Outcomes • Ave. follow up 6.8 years (Hazard Ratio) • Invasive breast Cancer = 26 vs 33/10,000 person yrs (0.77) • CHD = 49 vs 54/10,000 (0.91) • Venous Thromboembolic disease = 28 vs 21/10,000 (1.33) • Stroke = 44 vs 32/10,000 (1.39) • Fatal = 4 vs 4/10,000 (1.13) • Nonfatal = 32 vs 23/10,000 (1.39) • Colorectal cancer = 17 vs 16/10,000 (1.08) • Hip fracture = 11 vs 17/10,000 (0.61) • Vertebral fracture = 11 vs 17/10,000 (0.62)

  17. Menopausal Complaints: Treatments • Hormones vs non-hormones vs herbals • Efficacy

  18. Hormones Contraindicated • Breast CA • Endometrial CA • Undiagnosed vaginal bleeding • CHD • Venous thrombosis • Stroke • Pregnancy • What is not here, that is a CI on OCP’s?

  19. Normal Physiologic Changes of Aging

  20. Demographics • 34 million elderly now • 69 million in 2030 • Gerontology • Health in the aged • Absence of ds • Maintain function and comfort • Presence of satisfactory support systems

  21. Body Composition and Homeostasis • Decrease muscle mass • Increase body fat • Changes volume of distribution • Impaired baroreceptor • Orthostatic hypotension • Impaired thermoregulation

  22. Cardiovascular • Decrease LV compliance • Increased reliance on atria • More LVH • Stiffer arteries • Decreased beta-adrenergic responsiveness • Decreased max. HR with exercise

  23. Pulmonary • Decreased elastic recoil, airways collapse earlier • Decreased forced vital capacity, functional residual capacity, residual volume, FEV1 • Decreased ventilatory response and chemoreceptor function • Increased hypoxia and hypercapnia

  24. Renal • Decreased mass, # of glomeruli • Increased glomerulosclerosis • GFR slowly decreases • CrCl maintains • Decreased Na+ rentention, decreased responsiveness to AVP; less concentration of urine • Decreased thirst and drink response • Increased dehydration

  25. Endocrine • Decreased glucose tolerance • Independent of obesity and inactivity • FG decreases 1 mg/dL/decade • Increased insulin resistance • Decreased GH, IGF-1 • Give elderly men GH, increases lean body mass

  26. Immunologic • Decreased T-cell activity • Decreased Ab response to foreign antigen • Increased autoantibodies

  27. Specific Geriatric Issues Other assessments to be made.

  28. Cognitive Function • Normal decline • Dementia • Alzheimer’s • Vascular • Others • Depression • Medications • EtOH • MMSE

  29. Sensory • Visual • Auditory • Balance

  30. Incontinence • Types • Risk factors • Assess • Tests • Treatment

  31. Types of Incontinence • Urge • Stress • Functional • Overflow • Mixed

  32. Fall Risks • Intrinsic • Person oriented issues… • Mobility • “Get up and go” test • Extrinsic • Environment

  33. Polypharmacy • Medication List • Drug-drug interactions • Altered pharmacokinetics, pharmacodynamics • Herbals • OTC

  34. Osteoporosis • Screening • Risk Factors • Treatments

  35. Others • Abuse • Sexuality • Vaccinations • Financial • Support System • Driving

  36. Screening • Thyroid • Cancer • Sxs • Pap • Mammogram • Colonoscopy • Lipids

  37. Questions??? Thank you very much for your participation!! Good luck on your shelf!

More Related